NRX Pharmaceuticals (NRXP) Current Assets (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Current Assets data on file, last reported at $7.4 million in Q1 2026.

• On a quarterly basis, Current Assets rose 1.45% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 1.45% increase from a year earlier, with the FY2025 full-year figure at $8.9 million, up 169.29% from the prior year.
• Current Assets for Q1 2026 stood at $7.4 million, down from $8.9 million in the prior quarter.
• Over the last five years, Current Assets for NRXP reached as high as $43.6 million in Q1 2022 and fell as low as $3.3 million in Q4 2024.
• Historically, Current Assets has averaged $14.3 million across 5 years, with a median of $8.9 million in 2025.
• Across the five-year window, Current Assets surged 72875.69% in 2022 and plunged 84.62% in 2024, its largest moves.
• Year by year, Current Assets stood at $25.8 million in 2022, then plunged by 73.31% to $6.9 million in 2023, then sank by 52.03% to $3.3 million in 2024, then soared by 169.29% to $8.9 million in 2025, then fell by 17.22% to $7.4 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $7.4 million in Q1 2026, $8.9 million in Q4 2025, and $11.9 million in Q3 2025.